HK1162971A1 - Methods of using sustained release aminopyridine compositions - Google Patents

Methods of using sustained release aminopyridine compositions

Info

Publication number
HK1162971A1
HK1162971A1 HK12103854.5A HK12103854A HK1162971A1 HK 1162971 A1 HK1162971 A1 HK 1162971A1 HK 12103854 A HK12103854 A HK 12103854A HK 1162971 A1 HK1162971 A1 HK 1162971A1
Authority
HK
Hong Kong
Prior art keywords
composition
sustained release
methods
treatment
therapeutically effective
Prior art date
Application number
HK12103854.5A
Other languages
English (en)
Inventor
Andrew R Blight
Ron Cohen
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35061389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1162971(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of HK1162971A1 publication Critical patent/HK1162971A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
HK12103854.5A 2004-04-09 2012-04-18 Methods of using sustained release aminopyridine compositions HK1162971A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56089404P 2004-04-09 2004-04-09
US11/102,559 US8354437B2 (en) 2004-04-09 2005-04-08 Method of using sustained release aminopyridine compositions

Publications (1)

Publication Number Publication Date
HK1162971A1 true HK1162971A1 (en) 2012-09-07

Family

ID=35061389

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12103854.5A HK1162971A1 (en) 2004-04-09 2012-04-18 Methods of using sustained release aminopyridine compositions

Country Status (21)

Country Link
US (13) US8354437B2 (fr)
EP (5) EP3922248A1 (fr)
JP (4) JP5736100B2 (fr)
AT (1) ATE511841T1 (fr)
AU (1) AU2005232732B2 (fr)
CA (2) CA2870734C (fr)
CY (4) CY1111754T1 (fr)
DK (2) DK2377536T4 (fr)
ES (2) ES2367707T5 (fr)
FI (2) FI1732548T4 (fr)
HK (1) HK1162971A1 (fr)
HR (2) HRP20110497T4 (fr)
HU (1) HUE046320T2 (fr)
LU (2) LU91933I2 (fr)
ME (2) ME01721B (fr)
MX (3) MX370434B (fr)
PL (2) PL2377536T5 (fr)
PT (2) PT1732548E (fr)
RS (2) RS53371B2 (fr)
SI (2) SI2377536T2 (fr)
WO (1) WO2005099701A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007826B2 (en) * 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
AU2013206188B2 (en) * 2005-09-23 2016-04-14 Acorda Therapeutics, Inc. Method, apparatus and software for identifying responders in a clinical environment
TW201010703A (en) * 2008-09-10 2010-03-16 Acorda Therapeutics Inc Methods of using sustained release aminopyridine compositions
EA022755B1 (ru) * 2009-02-11 2016-02-29 Акорда Терапьютикс, Инк. Способы длительной терапии с применением аминопиридинов
JO3348B1 (ar) * 2009-08-11 2019-03-13 Acorda Therapeutics Inc استخدام 4- بايريدين امينو لتحسين الادراك العصبي و/او التلف النفسي لدى مرضى يعانون من نقص النُخاعين وغير ذلك من امراض الجهاز العصبي
TW201125562A (en) * 2009-09-04 2011-08-01 Acorda Therapeutics Inc Sustained release fampridine treatment in patients with multiple sclerosis
US20130030025A1 (en) * 2011-01-28 2013-01-31 Wessel Thomas C Use of potassium channel blockers to treat cerebral palsy
US8924325B1 (en) * 2011-02-08 2014-12-30 Lockheed Martin Corporation Computerized target hostility determination and countermeasure
WO2013003708A1 (fr) 2011-06-30 2013-01-03 Biomarin Pharmaceuticals, Inc. Méthodes d'administration de 3,4-diaminopyridine
TWI592156B (zh) 2011-10-04 2017-07-21 艾可達醫療公司 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法
BR112014020102A8 (pt) 2012-02-13 2017-07-11 Acorda Therapeutics Inc Método para o tratamento de uma insuficiência de marcha e/ou equilíbrio em um paciente com esclerose múltipla, método para o tramento de uma deficiência no equilíbrio estacionário e método para aumentar o comprimento do passo, diminuir a largura do passo ou diminuir a oscilação
WO2014028387A1 (fr) 2012-08-13 2014-02-20 Acorda Therapeutics, Inc. Méthodes d'amélioration de la capacité de marche chez des patients atteints de sclérose en plaques à l'aide d'une aminopyridine
WO2014093475A1 (fr) 2012-12-11 2014-06-19 Acorda Therapeutics, Inc. Méthodes pour traiter la maladie de parkinson faisant intervenir des aminopyridines
SG10201707543PA (en) 2013-03-14 2017-11-29 Alkermes Pharma Ireland Ltd Prodrugs of fumarates and their use in treating various deseases
WO2014151752A1 (fr) * 2013-03-15 2014-09-25 University Of Rochester Composition et procédés pour le traitement d'une lésion nerveuse périphérique
JP2016517856A (ja) 2013-04-15 2016-06-20 アコルダ セラピュティクス，インコーポレイテッド アミノピリジンを使用した、ある種の卒中に関連した感覚運動障害を治療するための方法
ES2879611T3 (es) 2015-02-08 2021-11-22 Alkermes Pharma Ireland Ltd Composiciones de profármaco de monometilfumarato
RU2580837C1 (ru) * 2015-05-05 2016-04-10 Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Московский Физико-Технический Институт (Государственный Университет)" Кристаллогидрат 4-аминопиридина, способ его получения, фармацевтическая композиция и способ лечения и/или профилактики на её основе
CN106511293B (zh) 2015-09-11 2020-08-04 法德生技药品股份有限公司 含有达方吡啶的缓释口服制剂及其用途
CA2999990A1 (fr) 2015-09-29 2017-04-06 Acorda Therapeutics, Inc. Compositions a liberation prolongee de 4-aminopyridine
WO2018186866A1 (fr) 2017-04-06 2018-10-11 Cobb Joseph E Jr Compositions à libération prolongée de 4-aminopyridine

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1082804A (en) 1912-11-19 1913-12-30 Gerald G Griffin Confetti-machine.
US3065143A (en) 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
CH415963A (de) 1964-09-04 1966-06-30 Wander Ag Dr A Masse zur Herstellung von Tabletten mit protrahierter Wirkung
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4508715A (en) * 1981-07-01 1985-04-02 University Of Georgia Research Foundation, Inc. Antagonism of central nervous system drugs by the administration of 4-aminopyridine alone or in combination with other drugs
US4386095A (en) * 1982-02-22 1983-05-31 Cornell Research Foundation, Inc. Diaminopyridines to improve cognition
IE53703B1 (en) 1982-12-13 1989-01-18 Elan Corp Plc Drug delivery device
IE54286B1 (en) 1983-01-18 1989-08-16 Elan Corp Plc Drug delivery device
US4851230A (en) * 1983-04-07 1989-07-25 Bristol-Myers Company Capsule shaped tablets
IE56459B1 (en) 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US4894240A (en) * 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
US4562196A (en) 1984-04-06 1985-12-31 Nelson Research & Development 2,4-Diaminopyridine as a pharmacologic agent
JPS6124516A (ja) 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤
US4812447A (en) 1985-10-22 1989-03-14 City Of Hope Method for the treatment of nervous system degeneration
US4760092A (en) 1985-10-29 1988-07-26 The Rockefeller University Treatment of demyelinating diseases
US4832957A (en) 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
IL86170A (en) * 1987-05-01 1992-12-01 Elan Transdermal Ltd Preparations and compositions comprising nicotine for percutaneous administration
IE64726B1 (en) 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
FI895821A0 (fi) * 1988-12-07 1989-12-05 Wellcome Found Farmaceutiskt aktiva cns foereningar.
US4948581A (en) 1989-02-17 1990-08-14 Dojin Iyaku-Kako Co., Ltd. Long acting diclofenac sodium preparation
IE82916B1 (en) 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
TW200462B (fr) * 1990-09-27 1993-02-21 Hoechst Roussel Pharma
CA2085785C (fr) 1992-12-18 2005-03-15 Robert R. Hansebout Utilisation de la 4-aminopyridine pour le traitement d'une affection neurologique
DE4321030A1 (de) * 1993-06-24 1995-01-05 Bayer Ag 4-bicyclisch substituierte Dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimittel
US5451409A (en) 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5952357A (en) * 1993-12-23 1999-09-14 Cornell Research Foundation, Inc. Treating diseases of the anterior horn cells
US6284473B1 (en) * 1995-10-02 2001-09-04 Uab Research Foundation P-cresol sulfate, a component of urinary myelin basic protein-like material, as a correlate of multiple sclerosis status
US7179486B1 (en) 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
US6288026B1 (en) * 1999-02-24 2001-09-11 Heinrich Exner Process and composition for treating diseases with an oil-in-water emulsion
US6600399B1 (en) 2002-02-05 2003-07-29 Roland Pierre Trandafir Transducer motor/generator assembly
WO2004082684A1 (fr) 2003-03-17 2004-09-30 Acorda Therapeutics Formulations orales stables d'aminopyridines et leurs utilisations
WO2004087160A1 (fr) * 2003-04-03 2004-10-14 Prana Biotechnology Ltd Traitement d'affections neurologiques
EP1651169A4 (fr) * 2003-08-01 2008-02-27 Medarex Inc Polytherapies pour la sclerose en plaques
US8007826B2 (en) * 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
WO2006130726A2 (fr) * 2005-06-01 2006-12-07 Teva Pharmaceutical Industries, Ltd. Utilisation du ladostigil pour traiter la sclerose en plaques
US20090150180A1 (en) 2005-09-23 2009-06-11 Ron Cohen Method, apparatus and solftware for identifying responders in clinical environment
TWM331106U (en) * 2007-11-12 2008-04-21 Syspotek Corp Solution counter with temperature sensor
TW201010703A (en) 2008-09-10 2010-03-16 Acorda Therapeutics Inc Methods of using sustained release aminopyridine compositions
WO2010090730A1 (fr) 2009-02-03 2010-08-12 Acorda Therapeutics, Inc. Procédé, appareil et logiciel pour identifier des sujets réactifs dans un environnement clinique
EA022755B1 (ru) 2009-02-11 2016-02-29 Акорда Терапьютикс, Инк. Способы длительной терапии с применением аминопиридинов
JO3348B1 (ar) 2009-08-11 2019-03-13 Acorda Therapeutics Inc استخدام 4- بايريدين امينو لتحسين الادراك العصبي و/او التلف النفسي لدى مرضى يعانون من نقص النُخاعين وغير ذلك من امراض الجهاز العصبي
TW201125562A (en) 2009-09-04 2011-08-01 Acorda Therapeutics Inc Sustained release fampridine treatment in patients with multiple sclerosis
US10255905B2 (en) 2016-06-10 2019-04-09 Google Llc Predicting pronunciations with word stress

Also Published As

Publication number Publication date
LU91933I2 (fr) 2013-01-18
EP2460521A1 (fr) 2012-06-06
JP2007532578A (ja) 2007-11-15
PL1732548T3 (pl) 2011-11-30
US20180200241A1 (en) 2018-07-19
US8440703B2 (en) 2013-05-14
US20160199358A1 (en) 2016-07-14
RS51808B9 (sr) 2019-06-28
ME01721B (me) 2014-09-20
EP1732548B2 (fr) 2023-08-30
DK2377536T3 (da) 2013-03-25
MX2019015036A (es) 2020-02-24
PL2377536T3 (pl) 2013-08-30
US8354437B2 (en) 2013-01-15
ME01836B (me) 2014-12-20
RS51808B2 (sr) 2023-12-29
EP1732548A4 (fr) 2009-06-03
JP2012188427A (ja) 2012-10-04
SI2377536T1 (sl) 2013-07-31
FIC20130042I1 (fi) 2013-08-13
CY2012004I2 (el) 2015-10-07
ES2367707T9 (es) 2012-07-05
EP2460521B1 (fr) 2019-06-12
PT2377536E (pt) 2013-04-11
ES2746354T3 (es) 2020-03-05
EP3922248A1 (fr) 2021-12-15
JP2015057451A (ja) 2015-03-26
RS53371B (en) 2014-10-31
LU92275I2 (fr) 2015-09-03
EP1732548B9 (fr) 2012-03-21
SI1732548T1 (sl) 2011-09-30
US20140039015A1 (en) 2014-02-06
LU92275I9 (fr) 2019-01-03
HRP20130424T4 (hr) 2022-10-28
HRP20130424T1 (en) 2013-06-30
HRP20110497T4 (hr) 2024-03-29
US20110166188A1 (en) 2011-07-07
RS51808B8 (sr) 2019-08-30
RS51808B (en) 2011-12-31
US20110166189A1 (en) 2011-07-07
CA2562277A1 (fr) 2005-10-27
CA2870734C (fr) 2022-08-16
RS53371B2 (sr) 2022-11-30
EP1732548A2 (fr) 2006-12-20
DK2377536T4 (da) 2022-11-07
JP5914626B2 (ja) 2016-05-11
EP2377536B1 (fr) 2013-03-06
HRP20110497T1 (hr) 2011-08-31
MXPA06011648A (es) 2008-10-31
CA2562277C (fr) 2015-01-27
CY2012004I1 (el) 2015-10-07
CY2013035I1 (el) 2020-05-29
CY1111754T1 (el) 2015-10-07
US20050228030A1 (en) 2005-10-13
EP2377536A1 (fr) 2011-10-19
US9925173B2 (en) 2018-03-27
ES2367707T5 (es) 2024-04-25
CA2870734A1 (fr) 2005-10-27
EP2377536B2 (fr) 2022-08-17
ATE511841T1 (de) 2011-06-15
US20150080436A1 (en) 2015-03-19
US20170273960A1 (en) 2017-09-28
WO2005099701A2 (fr) 2005-10-27
US20110166187A1 (en) 2011-07-07
HUE046320T2 (hu) 2020-02-28
US20120164078A1 (en) 2012-06-28
FI1732548T4 (fi) 2023-11-30
SI1732548T2 (sl) 2024-02-29
US20120064007A1 (en) 2012-03-15
WO2005099701A3 (fr) 2006-03-23
AU2005232732B2 (en) 2011-05-12
DK1732548T3 (da) 2011-09-26
MX370434B (es) 2019-12-13
EP2422782A1 (fr) 2012-02-29
SI2377536T2 (sl) 2022-11-30
CY1114073T1 (el) 2016-07-27
AU2005232732A1 (en) 2005-10-27
US20170071924A1 (en) 2017-03-16
DK1732548T4 (da) 2023-11-20
ES2367707T3 (es) 2011-11-07
US20170209422A1 (en) 2017-07-27
PL1732548T4 (pl) 2012-03-30
PT1732548E (pt) 2011-09-16
PL2377536T5 (pl) 2023-03-06
JP2015157861A (ja) 2015-09-03
EP1732548B1 (fr) 2011-06-08
JP5736100B2 (ja) 2015-06-17

Similar Documents

Publication Publication Date Title
HRP20130424T1 (en) Methods of using sustained release aminopyridine compositions
Bertollo et al. Characterization of the antinociceptive and anti-inflammatory activities of riboflavin in different experimental models
HUP0204163A2 (hu) Opioid agonistát és antagonistát tartalmazó szabályozott leadású készítmény és eljárás az előállítására
GB2431346C (en) A combination composition comprising paracetamol and ibuprofen
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
TW200633978A (en) 2,3,4,9-tetrahydro-1H-carbazole derivatives as crth2 receptor antagonists
WO2007059342A3 (fr) Procedes de traitement de maladie par le biais de copolymeres aleatoires
TW200738228A (en) Neramexane modified release matrix tablet
WO2007078443A3 (fr) Methodes visant a traiter une maladie a l'aide de copolymeres aleatoires
UY32109A (es) Métodos para utilizar composiciones de liberación sostenida de aminopiridina
HK1075450A1 (en) heterocyclic compunds, process for their preparation and pharmaceutical compositions containing thenm and thier use in medicine
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
MX2011011459A (es) Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos.
WO2005120542A3 (fr) Methodes de traitement de maladie a l'aide de copolymeres aleatoires
DK0991409T3 (da) Farmaceutiske tiagabinindeholdende præparater med reguleret frigivelse
Eap et al. S14. 02 Pharmacokinetics of methadone and Laam, and their clinical relevance

Legal Events

Date Code Title Description
AM43 Amendment of standard patent following opposition or revocation proceedings in the designated patent office (acc. sect 43 patent ordinance)